Sorafenib and Lenvatinib Treatment for Metastasis/Recurrence of Radioactive Iodine-refractory Differentiated Thyroid Carcinoma

Background/Aim: Radioactive iodine-refractory differentiated thyroid carcinoma (RR-DTC) has been treated with multi-kinase inhibitors (MKIs), e.g., sorafenib (SOR) and lenvatinib (LEN). We analyzed the outcomes of RR-DTC patients who underwent SOR or LEN treatment at Kuma Hospital. Patients and Meth...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:In Vivo
Prif Awduron: ITO, YASUHIRO, ONODA, NAOYOSHI, KUDO, TAKUMI, MASUOKA, HIROO, HIGASHIYAMA, TAKUYA, KIHARA, MINORU, MIYA, AKIHIRO, MIYAUCHI, AKIRA
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: International Institute of Anticancer Research 2021
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8045109/
https://ncbi.nlm.nih.gov/pubmed/33622902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.12350
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg